ILMN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IL

Mkt Cap

$39.63B

Volume

1.97M

Next Earnings

October 29th

Loading chart

IL

ILMNIllumina Inc

ILMN

Pay with—

Available Balance0.00

IL

Mkt Cap

$39.64B

Volume

1.97M

Next Earnings

October 29th

Chart Financials Earnings News About Insider Filings

Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?Illumina is positioned to potentially beat earnings estimates in its next quarterly report on October 29, 2026. The company has a strong track record of beating estimates, with an average surprise of 8.01% over the last two quarters. With a positive Earnings ESP of +9.16% and a Zacks Rank #2 (Buy), analysts have recently become bullish on the company's earnings prospects.Zacks Investment Research · Oct 16, 2026

Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 MillionSaudi Arabia's Non-Invasive Prenatal Testing (NIPT) market is projected to grow from US$52.50 million in 2025 to US$162.16 million by 2034, driven by a 13.35% CAGR. Growth is fueled by advances in next-generation sequencing, rising maternal age, increased healthcare investment, and expanding genetic testing capacity. Key players include Eurofins Scientific, Roche, Invitae, Illumina, Natera, Centogene, and Qiagen, with Riyadh and Jeddah leading regional adoption.GlobeNewswire Inc. · Oct 15, 2026

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?PBE is a smart beta ETF focused on biotechnology and genome companies with $412.99 million in assets. It has delivered strong year-to-date returns of 16.68% and one-year returns of 36.23%, but carries higher risk with a standard deviation of 20.18%. The fund charges a 0.59% expense ratio and holds concentrated positions in healthcare stocks like Natera, Illumina, and Biogen. Cheaper alternatives like XBI and IBB are available for investors seeking lower-cost options.Zacks Investment Research · Oct 14, 2026

Should Invesco S&P MidCap Quality ETF (XMHQ) Be on Your Investing Radar?The Invesco S&P MidCap Quality ETF (XMHQ) offers broad exposure to mid-cap blend stocks with $5.46 billion in assets and a competitive 0.25% expense ratio. The ETF has returned 11.95% year-to-date and 12.26% over the past year, with heavy allocation to Industrials (29.4%). It holds a Zacks ETF Rank of 2 (Buy), though larger competitors like Vanguard Morningstar Mid-Cap ETF and iShares Core S&P Mid-Cap ETF offer lower expense ratios.Zacks Investment Research · Oct 13, 2026

Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and AutomationThe global microfluidics market is projected to grow from $21.58 billion in 2025 to $48.04 billion by 2036, with a CAGR of 7.49%. Growth is driven by rising demand for rapid diagnostics, point-of-care testing, genomic analysis, and automated workflows. Microfluidic consumables dominate with 66.7% market share, while Asia-Pacific is expected to register the highest regional growth at 8.72% CAGR.GlobeNewswire Inc. · Oct 6, 2026

Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGRThe global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions.GlobeNewswire Inc. · Oct 5, 2026

Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsightThe global liver cancer diagnostics market is projected to grow from USD 10.5 billion in 2025 to USD 19.8 billion by 2034, driven by rising hepatocellular carcinoma incidence, increasing chronic liver disease prevalence, and advances in diagnostic technologies including liquid biopsy, AI-assisted imaging, and blood-based biomarkers. North America leads the market with 41% share, while Asia-Pacific is expected to be the fastest-growing region.GlobeNewswire Inc. · Oct 1, 2026

3 Reasons to Buy Grail (GRAL) Hand Over Fist in OctoberGrail, spun off from Illumina in 2024, develops the Galleri blood test for early cancer detection. The company has grown revenue from $93M (2023) to $147M (2025) through cash-only sales and is expected to reach $181M in 2026. An FDA panel recently endorsed premarket approval with three affirmative votes, potentially supporting FDA approval by 2027. Despite trading at 21x 2028 sales, analysts believe the stock could be undervalued if FDA approval comes early and adoption accelerates.The Motley Fool · Sep 30, 2026

Where Will Illumina Stock Be in 5 Years If Its AI Bet Pays Off?Illumina is developing an AI strategy centered on biological data from its sequencing technology. The company's initiatives, including the Billion Cell Atlas and expanded drugmaker partnerships, could create a new growth engine if it successfully converts its scientific advantages into recurring commercial revenue.The Motley Fool · Sep 30, 2026

REGN or ILMN: Which Is the Better Value Stock Right Now?A comparison of two Medical-Biomedical and Genetics stocks reveals that Regeneron (REGN) presents a better value opportunity than Illumina (ILMN) for value investors. REGN has a stronger Zacks Rank of #1 (Strong Buy) versus ILMN's #2 (Buy), along with significantly more attractive valuation metrics including a forward P/E of 14.16 versus ILMN's 50.77, and a PEG ratio of 1.23 versus 3.85.Zacks Investment Research · Sep 29, 2026

to start trading

IL

ILMNIllumina Inc

ILMN

Pay with—

Available Balance0.00

Your PositionYou don't own any ILMN yet.

Related Tickers

Earnings